CHMP recommends two new drugs for approval and rejects one

Japanese firm Kyowa Kirin's Parkinson's disease treatment was given a negative opinion at the council's meeting in July. Two other drugs were recommended for approval.

Photo: Rob Acket/EMA

The CHMP (Committee for Medicinal Products for Human use) did not have many drugs to consider in July.

The European Medicines Agency's expert panel only made recommendations in the case of three drugs. Of these, two were recommended for approval, whilst a negative opinion was adopted for the third.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs